US5120545A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Reduction or prevention of sensitization to drugs
Assignee: Alza Corp
•
Filing: 1990-08-03
•
Granted: 1992-06-09
•
Expires: 2010-08-03
Abstract
Abstract The present invention is directed to a method of reducing or preventing skin sensitization by inhibiting the immunological processing of a sensitizing drug as an antigen. The drug is sensitizing to humans, i.e., the drug is susceptible to inducing skin or mucosa sensitization in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Skin sensitization reduction or prevention is induced by coadministering to the skin or mucosa of the human: (a) a therapeutically effective amount of a sensitizing drug, at a therapeutically effective rate over a predetermined period of time; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the antigen processing of the drug. The system of the invention comprises a matrix adapted to be placed in sensitizing drug and antigen processing-inhibiting agent transmitting relation to the selected skin or mucosa site. The matrix contains sufficient amounts of the drug and the agent to continuously coadminister to the skin or mucosa site the drug, at a therapeutically effective rate and over a predetermined delivery period, and the antigen processing-inhibiting agent, at a rate and for a period of time sufficient to inhibit the processing of the drug as an antigen.
Inventors
- 👤 Philip W. Ledger
- 👤 Michel J. Cormier
- 👤 Alfred Amkraut
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 05:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0009; A61K33/00; A61K33/02; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
190 words
A method of reducing or preventing human skin sensitization during transdermal administration to a human of a sensitizing drug, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 2
Independent Claim
190 words
A method of reducing or preventing human skin sensitization during transdermal administration to a human of a sensitizing drug, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 3
Dependent Claim
30 words
A method according to claim 1 wherein the drug and the agent are coadministered transdermally from a matrix placed in drug and agent transmitting relation with the skin or mucosa.
Claim 4
Independent Claim
199 words
A method of reducing or preventing the elicitation of human skin sensitization during transdermal administration to a human of a sensitizing drug to which the human is sensitized, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 5
Independent Claim
199 words
A method of reducing or preventing the elicitation of human skin sensitization during transdermal administration to a human of a sensitizing drug to which the human is sensitized, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 6
Dependent Claim
30 words
A method according to claim 3 wherein the drug and the agent are coadministered transdermally from a matrix placed in drug and agent transmitting relation with the skin or mucosa.
Claim 7
Dependent Claim
17 words
A method according to claim 3 wherein the drug is propranolol and the agent is ammonium chloride.
Claim 8
Dependent Claim
17 words
A method according to claim 3 wherein the drug is tetracaine and the agent is ammonium chloride.
Claim 9
Independent Claim
193 words
A method of reducing or preventing the induction of human skin sensitization during transdermal administration to a human of a sensitizing drug, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 10
Independent Claim
193 words
A method of reducing or preventing the induction of human skin sensitization during transdermal administration to a human of a sensitizing drug, which drug is susceptible to inducing skin sensitization in the human when the drug is transdermally administered, the method comprising coadministering to a selected site on the skin or mucosa of the human: (a) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (b) an antigen processing-inhibiting agent in an amount effective to inhibit the processing of the drug as an antigen, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt%, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt%.
Claim 11
Dependent Claim
30 words
A method according to claim 7 wherein the drug and the agent are coadministered transdermally from a matrix placed in drug and agent transmitting relation with the skin or mucosa.
Claim 12
Dependent Claim
236 words
A transdermal drug delivery device for transdermally administering a sensitizing drug to a human, which drug is susceptible to inducing skin or mucosal sensitization in the human when the drug is transdermally delivered, the device comprising: (a) a matrix adapted to be placed in drug and antigen processing-inhibiting agent transmitting relation with a selected site on the skin or mucosa of the human, the matrix containing sufficient amounts of drug and antigen processing-inhibiting agent to continuously and co-extensively administer to the skin or mucosal site: (1) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (2) an antigen processing-inhibiting amount of the antigen processing-inhibiting agent capable of inhibiting processing of the drug as an antigent to reduce or prevent sensitization to the skin or mucosa, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt %, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt %.
Claim 13
Dependent Claim
236 words
A transdermal drug delivery device for transdermally administering a sensitizing drug to a human, which drug is susceptible to inducing skin or mucosal sensitization in the human when the drug is transdermally delivered, the device comprising: (a) a matrix adapted to be placed in drug and antigen processing-inhibiting agent transmitting relation with a selected site on the skin or mucosa of the human, the matrix containing sufficient amounts of drug and antigen processing-inhibiting agent to continuously and co-extensively administer to the skin or mucosal site: (1) a therapeutically effective amount of the sensitizing drug, at a therapeutically effective rate over a predetermined period of time, wherein the drug is selected from ketoprofen, piroxicam, indomethacin, scopolamine, imipramine, desipramine, nortriptyline, clemastine, chlorpheniramine, diphenhydramine, daunorubicin, chloroquine, quinacrine, chlorpromazine, fluphenazine, perphenazine, propranolol, alprenolol, betaxolol, labetalol, metoprolol, timolol, pindolol, atenolol, tetracaine, prilocaine, buprenorphine, naloxone, naltrexone, phentolamine, phenylpropanolamine, ephedrine, mephentermine, bitolterol, tolazoline, streptomycin, gentamycin, somatropin, somatotropin, somatostatin, insulin, insulin-like growth factor (somatomedins), luteinizing hormone releasing hormone, tissue plasminogen activator, and growth hormone releasing hormone; and (2) an antigen processing-inhibiting amount of the antigen processing-inhibiting agent capable of inhibiting processing of the drug as an antigent to reduce or prevent sensitization to the skin or mucosa, wherein the agent is either an ionophore, in an amount of from about 0.01 wt% to about 5 wt %, or an amphiphilic amine, in an amount of from about 0.2 wt% to about 20 wt %.
Claim 14
Dependent Claim
17 words
A method according to claim 1 wherein the drug is propranolol and the agent is ammonium chloride.
Claim 15
Dependent Claim
17 words
A method according to claim 1 wherein the drug is tetracaine and the agent is ammonium chloride.
Claim 16
Dependent Claim
17 words
A device according to claim 9 wherein the drug is propranolol and the agent is ammonium chloride.
Claim 17
Dependent Claim
17 words
A device according to claim 9 wherein the drug is tetracaine and the agent is ammonium chloride.
References Cited (Backward Citations)
US3598122A
Cited
US3598122B1
Cited
US3598123A
Cited
US3991755A
Cited
US4274420A
Cited
US4141359A
Cited
US4325367A
Cited
US4250878A
Cited
US4391278A
Cited
US4398545A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4474570A
Cited
US4419092A
Cited
US4559222A
Cited
US4557723A
Cited
US4640689A
Cited
US4708716A
Cited
US4573995A
Cited
US4702732A
Cited
US4988705A
Cited
US4885154A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-09 | 1995-12-09 | 1996-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-09 | 1999-12-09 | 2000-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-09 | 2003-12-09 | 2004-06-09 | $7700.00 | Window Closed / Lapsed |